$AXSM

$TGTX

$TGTX Q2 2025 webcast "We estimate one in every three new IV anti-CD20 patients are prescribed Briumvi" With patients generally staying on treatment for the long term and 33% of new patient going onto Briumvi, this could hit ~$1bn in annual sales around 2028

$TGTX Anything under $30 looks like a gift to me (buying it at a Nov '24 stock price but with a 72% increase in Briumvi revenues). Hoping to see it bounce back to at least >$35 in the short term.

$NWBO 600 days since the MAA was filed with the MHRA [21st Dec '23] 134 days since the MHRA officially stated it had cleared all backlogs [31st March '25] Yet still no decision announced by the company? And somehow the shareholders aren't livid? Cc: Adam Feuerstein ✡️